NEW YORK ― At the OSN New York meeting here, William B. Trattler, MD, discusses his presentation on surface ablation in thin corneas and corneas with forme fruste keratoconus.
Author: Healio ophthalmology
VIDEO: Visual outcomes ‘excellent’ with surface ablation after LASIK flap complication
NEW YORK ― At the OSN New York meeting here, Priyanka Sood, MD, recommends waiting until refractive stability is achieved in cases of re-treatment after LASIK flap complications. In 11 of 14 cases at her clinic, refractive stability was achieved within 2 weeks of the initial abandoned procedure, and re-treatment with surface ablation on top of the flap resulted in “excellent visual outcomes.”
VIDEO: Discuss cataract surgery options with keratoconus patients
NEW YORK ― At the OSN New York meeting here, Jennifer M. Loh, MD, discusses best practices for performing cataract surgery in patients with keratoconus. She stresses the importance of communicating the options with patients in advance of surgery as well as the need to tailor surgery to each patient’s specific condition.
Data monitoring key to tracking, improving toric IOL outcomes
NEW YORK — Keeping extensive records of accuracy, tracking outcomes and measuring accurately are key to improving surgical outcomes after toric IOL implantation and reducing the need for enhancement following the procedure, according to a speaker here. “You want to automate as much as possible,” Denise M. Visco, MD, said at the OSN New York meeting. “It’s critical that if you put a lot of effort into measuring, you need to put a lot of effort into marking. You want to track your results and go in the direction of (Read more...)
Non-IV sedation eases anxiety for patients undergoing cataract surgery
NEW YORK — Patients who received sublingual anesthesia prior to cataract surgery had less anxiety than those who underwent an intravenous form of anesthesia for cataract surgery, according to a presenter here.“Sublingual sedation approaches decrease the need for IVs. You get a predictable dosing, …it allows a sublingual administration, patients really like it, and you get a little bit better focusing on the light and a ketamine stare,” John P. Berdahl, MD, said at the OSN New York meeting.
FDA takes action in October
In October, the FDA approved, cleared, responded to and issued review status for products and devices in the ophthalmic space. Here are the articles:
VIDEO: FLACS results continue to improve
At Hawaiian Eye 2016, Kevin M. Miller, MD, points out the good and the bad aspects of femtosecond laser-assisted cataract surgery compared with conventional cataract surgery.
VIDEO: Consider initial therapy with SLT for glaucoma, speaker says
At Hawaiian Eye 2016, L. Jay Katz, MD, FACS, of Wills Eye Hospital discusses the use of selective laser trabeculoplasty as a substitute for glaucoma medications in patients with open angle glaucoma. As first-line therapy, Katz says that SLT compares fa…
Aerie Pharmaceuticals reports third quarter loss of $23.8 million
Aerie Pharmaceuticals reported a net loss of $23.8 million, or $0.81 per share, in the third quarter, compared with a net loss of $18 million, or $0.69 per share, in the third quarter of 2015.A company press release attributed $23.3 million of the loss…
Report: Ocular syphilis found in 0.6% of syphilis cases
Eight jurisdictions in the United States reviewed syphilis cases in 2014-2015 and found 0.6% of the patients had symptoms consistent with ocular syphilis, according to a report. Ocular syphilis clusters were reported in Washington and California in ear…
PUBLICATION EXCLUSIVE: Managing excessive residual astigmatism after toric IOL implantation
Even though 90% of our toric IOL cases should be within 0.5 D of residual astigmatism, there will be cases in which the outcome is intolerable for the patient and something must be done. The following discussion explains the proper management.The first step is to reassure the patient that an adjustment can easily be made and to make sure that the refraction is stable. Toric IOLs rarely rotate after implantation, but the wound is not stable until at least 3 weeks after surgery with a 2.5-mm temporal incision and will (Read more...)
Second Sight reports gross loss, higher net loss for third quarter
Second Sight Medical Products reported a gross loss of $1.4 million in the third quarter compared with a gross profit of $1.5 million in the third quarter of 2015.A company press release attributed the loss to lower revenues, production costs and exces…
Study: Basketball leading cause of sports-related ocular trauma in men
A study found that approximately 30,000 people present to the emergency department each year after experiencing eye injuries related to sports, but appropriate protective eyewear could potentially reduce the number of sports-related ocular trauma incid…
EyeGate Pharmaceuticals reports higher net loss in third quarter
EyeGate Pharmaceuticals reported a $3.377 million net loss in the third quarter, compared with a $1.356 million net loss in the third quarter of 2015, according to a company press release.A phase 3 confirmatory trial of EGP-437 for the treatment of ant…
Combination of squalamine, ranibizumab improves BCVA in eyes with retinal vein occlusion
Patients with macular edema secondary to retinal vein occlusion who received a combination of squalamine and ranibizumab had a better improvement in best corrected visual acuity than patients who received ranibizumab alone, according to a study. The si…
CMS finalizes updated payment rates, policy changes affecting OPPS and ASCs
The Centers for Medicare and Medicaid Services has issued a final rule with comment period that updates payment rates and makes policy changes that affect the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center payment system …
New CPT codes to cover programming of Argus II retinal prosthesis system
The American Medical Association Current Procedural Terminology Editorial Panel approved two new Category III CPT codes for programming the Argus II retinal prosthesis system, Second Sight Medical Products announced in a press release.In addition, CMS …
Allergan reports Q3 financial results
Allergan plc reported its continuing operations performance for the third quarter of 2016, including total net revenues of $3.6 billion, a 4% increase compared with the prior year quarter.Strong performance from key brands in eye care, aesthetics, plas…
BLOG: The best thing I saw at AAO? Allergan’s social contract
The AAO meeting is always a great time to catch up with friends and learn about new technologies. To be sure, this meeting had some exciting new approvals, like Shire’s Xiidra for dry eye, Alcon’s CyPass micro-stent for glaucoma, and the AMO Symfony implant—the first extended depth-of-focus implant in the U.S. While technology is great, I was most impressed with Allergan’s announcement by CEO Brent Saunders of the company’s new social contract.
Under what circumstances would you consider the off-label combination of corneal inlay surgery and LASIK?
PointWith the Kamra inlay, we have found the “sweet spot” for our happiest patients is a refractive error around –0.75 D. However, at least half of our presbyopic patients present with a refractive error significantly different from this value. In these cases, we have used LASIK to correct the refraction to this value.